Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

I-Mab Reports IL-6 Inhibitor Effective in Phase II Ulcerative Colitis Test

publication date: Apr 27, 2021

Shanghai's I-Mab reported positive topline data from a Phase II trial of a selective IL-6 inhibitor in patients with ulcerative colitis. I-Mab says olamkicept is the only clinical stage IL-6 inhibitor that works via a trans-signaling mechanism. Other IL-6 therapies cause total inhibition of IL-6 signaling, including inhibiting homeostatic effects, which is associated with significant adverse events. In the double-blind Phase II trial, olamkicept met its primary and secondary endpoints. I-Mab acquired greater China rights to the IL-6 antagonist in 2016 from Swizterland's Ferring Pharma. More details....

Stock Symbol: (NSDQ: IMAB)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital